AVITA Medical study shows PermeaDerm costs 70% less than allograft

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. QQQ
8. UNFI
9. SPY
10. ASO

Go back to AVITA Medical study shows PermeaDerm costs 70% less than allograft
(NASDAQ: RCEL) Delayed: 10.41 --0 (-0%)
Previous Close $10.41    52 Week High $ 
Open $10.41    52 Week Low $ 
Day High $10.41    P/E N/A 
Day Low $10.41    EPS $ 
Volume 6